Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein
Abstract Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the treatment of acute lymphoblastic leukemia (ALL). The t(4;11)(q21;q23) chromosomal translocation that leads to the expr...
Guardado en:
Autores principales: | Tyler W. Jenkins, Sondra L. Downey-Kopyscinski, Jennifer L. Fields, Gilbert J. Rahme, William C. Colley, Mark A. Israel, Andrey V. Maksimenko, Steven N. Fiering, Alexei F. Kisselev |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f287ffb014d44282a148d0dbf994ac53 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A human fetal liver-derived infant MLL-AF4 acute lymphoblastic leukemia model reveals a distinct fetal gene expression program
por: Siobhan Rice, et al.
Publicado: (2021) -
MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors
por: Xinyue Chen, et al.
Publicado: (2019) -
Publisher Correction: MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors
por: Xinyue Chen, et al.
Publicado: (2020) -
TIFAB accelerates MLL-AF9−Induced acute myeloid leukemia through upregulation of HOXA9
por: Jinming Zhao, et al.
Publicado: (2021) -
On the Role of the Immunoproteasome in Protein Homeostasis
por: Michael Basler, et al.
Publicado: (2021)